Full Press Release Details
Tonix Pharmaceuticals Holding Corp. 8-K
Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL
Expects the Data to Satisfy Pharmacokinetic Requirements for Potential New Drug Applications for TNX-102 SL for PTSD and Fibromyalgia
of a Food Effect for TNX-102 SL Supports Predictability of Therapeutic Effect
YORK, January 24, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix), a clinical-stage biopharmaceutical
company, today announced that it has completed the required fed-fasting and dose proportionality tests of TNX-102 SL in healthy
volunteers to support the New Drug Application (NDA) of TNX-102 SL for the treatment of posttraumatic stress disorder (PTSD) and
preliminary results of the study showed no significant effect of a fatty meal on the rate or extent of absorption of TNX-102 SL
5.6 mg administered as 2 x 2.8 mg sublingual tablets. The absence of a food effect is consistent with transmucosal absorption
after sublingual administration. Oral cyclobenzaprine products approved for treating muscle spasm have significant increases in
absorption with food. Food effects which change plasma drug levels can add unpredictability for patients in terms of therapeutic
benefits or side effects. The study also showed the rate and extent of absorption of cyclobenzaprine increase in a dose proportional
manner from 2.8 mg to 5.6 mg for TNX-102 SL. The dose proportionality observed in this study confirms an earlier study using a
prototype 2.4 mg formulation.
Tonix Pharmaceuticals Holding Corp.
is a clinical-stage biopharmaceutical company focused on discovering and developing small molecules and biologics to treat psychiatric,
pain and addiction conditions. Tonix's lead product candidate, TNX-102 SL*, is in Phase 3 development as a bedtime treatment
for PTSD (trade name Tonmya**) and fibromyalgia. The Phase 3 RECOVERY trial (P302) in PTSD is currently enrolling and results
from an interim analysis for a potential sample size adjustment are expected in the first quarter of 2020 and topline data are
expected in the second quarter of 2020 if the sample size remains the same. TNX-102 SL for PTSD has U.S. Food and Drug Administration
(FDA) Breakthrough Therapy Designation. Tonix has started enrollment in the Phase 3 RELIEF trial in fibromyalgia. TNX-102 SL is
also in development for agitation in Alzheimer's disease and alcohol use disorder (AUD). The agitation in Alzheimer's
disease program is Phase 2 ready with FDA Fast Track designation and the development for AUD is in the pre-Investigational New
Drug (IND) application stage. TNX-601 CR (tianeptine oxalate controlled-release tablets) is in development as a daytime treatment
for PTSD, as well as for depression. The first efficacy study will be performed outside the U.S. and it is expected to be IND-ready
in 2020. TNX-1600 (a triple reuptake inhibitor) is a third product candidate being developed for PTSD, as a daytime treatment.
Tonix s programs for treating addiction conditions also include TNX-1300*** (double-mutant cocaine esterase), which is in
Phase 2 development for the treatment of cocaine intoxication and has FDA Breakthrough Therapy Designation. Tonix's preclinical
pipeline includes TNX-1500 (anti-CD154), a monoclonal antibody being developed to prevent and treat organ transplant rejection
and autoimmune conditions, and TNX-1700 (rTFF2), a biologic being developed to treat gastric and pancreatic cancers. Finally,
TNX-801 (live virus vaccine for percutaneous [scarification] administration) to potentially prevent smallpox and TNX-701 (undisclosed
small molecule) to prevent radiation effects are being advanced as medical countermeasures to improve biodefense.
SL (cyclobenzaprine HCl sublingual tablets) is an investigational new drug and has not been approved for any indication.
has been conditionally accepted by the FDA as the proposed trade name for TNX-102 SL for the treatment of PTSD.
(T172R/G173Q double-mutant cocaine esterase 200 mg, i.v. solution) is an investigational new biologic and has not been approved
press release and further information about Tonix can be found at www.tonixpharma.com.
statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.
These statements may be identified by the use of forward-looking words such as "anticipate," "believe,"
"forecast," "estimate," "expect," and "intend," among others. These forward-looking
statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors
that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include,
but are not limited to, risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations;
risks related to the timing and progress of clinical development of our product candidates; our need for additional financing;
uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research
and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development,
there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake
an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual
Report on Form 10-K for the year ended December 31, 2018, as filed with the Securities and Exchange Commission (the "SEC")
on March 18, 2019, and periodic reports on Form 10-Q filed with the SEC on or after the date thereof. Tonix does not undertake
any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise,
except as required by law.